Facial discoid dermatosis (FDD) is a rare dermatosis first described in 2010 by Ko et al.1 It is characterized by well-demarcated, annular, pink-orange, scaly papules and plaques localized on the face and occasionally the neck. FDD remains a diagnostic and therapeutic challenge, as it is often misdiagnosed as psoriasis, seborrheic dermatitis, discoid lupus erythematosus, pityriasis rubra pilaris (PRP), or granulomatous rosacea, and is frequently resistant to conventional therapies.2 Ruxolitinib is a topical selective JAK1/2 inhibitor approved for non-segmental vitiligo,3 and has also demonstrated efficacy in atopic dermatitis.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: